184 related articles for article (PubMed ID: 23102022)
21. Grape seed proanthocyanidin extract reverses multidrug resistance in HL-60/ADR cells via inhibition of the PI3K/Akt signaling pathway.
Lin KN; Jiang YL; Zhang SG; Huang SY; Li H
Biomed Pharmacother; 2020 May; 125():109885. PubMed ID: 32007917
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
Minderman H; Zhou Y; O'Loughlin KL; Baer MR
Cancer Chemother Pharmacol; 2007 Jul; 60(2):245-55. PubMed ID: 17096161
[TBL] [Abstract][Full Text] [Related]
23. The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells.
Ascione A; Cianfriglia M; Dupuis ML; Mallano A; Sau A; Pellizzari Tregno F; Pezzola S; Caccuri AM
Cancer Chemother Pharmacol; 2009 Jul; 64(2):419-24. PubMed ID: 19288261
[TBL] [Abstract][Full Text] [Related]
24. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
[TBL] [Abstract][Full Text] [Related]
25. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.
Kelly KR; Nawrocki ST; Espitia CM; Zhang M; Yang JJ; Padmanabhan S; Ecsedy J; Giles FJ; Carew JS
Int J Cancer; 2012 Dec; 131(11):2693-703. PubMed ID: 22488249
[TBL] [Abstract][Full Text] [Related]
26. SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells.
Xu SW; Law BYK; Qu SLQ; Hamdoun S; Chen J; Zhang W; Guo JR; Wu AG; Mok SWF; Zhang DW; Xia C; Sugimoto Y; Efferth T; Liu L; Wong VKW
Pharmacol Res; 2020 Mar; 153():104660. PubMed ID: 31982489
[TBL] [Abstract][Full Text] [Related]
27. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
[TBL] [Abstract][Full Text] [Related]
28. In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells.
Zhang L; Wang Z; Khishignyam T; Chen T; Zhou C; Zhang Z; Jin M; Wang R; Qiu Y; Kong D
Biomed Pharmacother; 2018 Jul; 103():1069-1078. PubMed ID: 29710665
[TBL] [Abstract][Full Text] [Related]
29. A new apoptosis inhibitor, CIAPIN1 (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax.
Li X; Hong L; Zhao Y; Jin H; Fan R; Du R; Xia L; Luo G; Fan D
Biochem Cell Biol; 2007 Dec; 85(6):741-50. PubMed ID: 18059532
[TBL] [Abstract][Full Text] [Related]
30. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
31. sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell.
Tian D; Das SG; Doshi JM; Peng J; Lin J; Xing C
Cancer Lett; 2008 Feb; 259(2):198-208. PubMed ID: 18037229
[TBL] [Abstract][Full Text] [Related]
32. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines.
Nuessler V; Stötzer O; Gullis E; Pelka-Fleischer R; Pogrebniak A; Gieseler F; Wilmanns W
Leukemia; 1999 Nov; 13(11):1864-72. PubMed ID: 10557064
[TBL] [Abstract][Full Text] [Related]
33. Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review.
Fajardo-Orduña GR; Ledesma-Martínez E; Aguiñiga-Sánchez I; Mora-García ML; Weiss-Steider B; Santiago-Osorio E
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066940
[TBL] [Abstract][Full Text] [Related]
34. Design real-time reversal of tumor multidrug resistance cleverly with shortened carbon nanotubes.
Wu P; Li S; Zhang H
Drug Des Devel Ther; 2014; 8():2431-8. PubMed ID: 25525333
[TBL] [Abstract][Full Text] [Related]
35. The pterocarpanquinone LQB‑118 compound induces apoptosis of cytarabine‑resistant acute myeloid leukemia cells.
Hancio T; Mazzoccoli L; Guimarães G; Robaina M; Mendonça BDS; Nestal De Moraes G; Monte-Mor BDCR; Mayumi Gutiyama L; De Carvalho LO; Netto CD; Costa PRR; De Faria FCC; Maia RC
Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33786613
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
[TBL] [Abstract][Full Text] [Related]
37. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
38. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
[TBL] [Abstract][Full Text] [Related]
39. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.
Lu F; Zhang J; Ji M; Li P; Du Y; Wang H; Zang S; Ma D; Sun X; Ji C
Int J Oncol; 2014 Jul; 45(1):383-92. PubMed ID: 24756163
[TBL] [Abstract][Full Text] [Related]
40. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
